Core Viewpoint - Watson Bio continues to strengthen its core competitiveness and cultivate new growth momentum in the vaccine industry despite common development challenges, achieving approximately 1.154 billion yuan in revenue and a net profit of about 43.16 million yuan in the first half of 2025 [1] Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of approximately 1.154 billion yuan and a net profit attributable to shareholders of approximately 43.16 million yuan [1] - The company plans to distribute cash dividends of 0.30 yuan per 10 shares, amounting to an estimated total payout of about 47.98 million yuan, reflecting strong cash reserves and a commitment to shareholder returns [5] Group 2: International Expansion - In the first half of 2025, Watson Bio's overseas business revenue reached 214 million yuan, with new export markets including Ghana and Myanmar, expanding its international market presence [2] - The company has exported over 63 million doses of its products to 24 countries and regions, maintaining a leading position among domestic vaccine companies in terms of export volume (excluding COVID-19 vaccines) [2] Group 3: Strategic Initiatives - Watson Bio has entered the micro-ecological health and functional nutrition intervention fields, signing exclusive licensing agreements to develop and commercialize core microbiome technologies in mainland China, Hong Kong, and Macau [3] - The company is establishing a synthetic biology platform in collaboration with local universities and research institutions, focusing on the industrialization of natural products and functional proteins [4] Group 4: Social Responsibility - In the first half of 2025, the company donated over 3,000 doses of bivalent HPV vaccines, demonstrating its commitment to social responsibility and women's health [5] - The company emphasizes the importance of fulfilling social responsibilities while pursuing business development, aiming for high-quality and sustainable growth [6]

证券代码：300142 证券简称：沃森生物 公告编号：2025-046 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 是否以公积金转增股本 □是 √否 公司经本次董事会审议通过的利润分配预案为：以2025年半年度权益分派实施公告中确定的股权登记日 当日的公司总股本扣除公司回购专用证券账户上的股份数后的股本为基数，向全体股东每10股派发现金 红利0.30元（含税），送红股0股（含税），不以公积金转增股本。 □是 √否 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 2、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 ■ 3、公司股东数量及持股情况 单位：股 ■ 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 □适用 √不适用 前10名股东及前10名无限 ...

Core Viewpoint - The company has approved a profit distribution plan for the first half of 2025, which aligns with its actual situation and complies with relevant laws and regulations, aiming to ensure sustainable and stable development [1][2][3] Summary by Sections 1. Review Process - The board of directors believes the profit distribution plan is legitimate, compliant, and reasonable, matching the company's development strategy [1][2] - The supervisory board agrees with the proposal, stating it aligns with the company's actual situation and regulations regarding cash dividends [1][2] 2. Profit Distribution Plan Details - The net profit attributable to shareholders for the first half of 2025 is 43,160,638.40 yuan, while the parent company's net profit is 2,727,762,437.59 yuan [2] - The total undistributed profits as of June 30, 2025, are 3,056,170,567.46 yuan for the consolidated statements and 2,999,321,198.71 yuan for the parent company [2] - The proposed cash dividend is 0.30 yuan per 10 shares (including tax), with no stock dividends or capital reserve transfers [2][3] 3. Reasonableness of the Profit Distribution Plan - The plan considers industry characteristics, development stage, operating model, profitability, debt repayment ability, and future funding needs [3] - It aims to balance reasonable returns for shareholders while ensuring the company's operational and developmental needs are met [3]

Core Insights - Watson Bio (300142.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its business operations [1] Financial Performance - The company achieved an operating revenue of 1.154 billion yuan, representing a year-on-year decrease of 19.47% [1] - The net profit attributable to shareholders of the listed company was 43.1606 million yuan, down 74.69% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 28.4427 million yuan, reflecting an 80.52% year-on-year decline [1] - Basic earnings per share were reported at 0.0273 yuan [1]

Core Insights - The HPV vaccine market in China has shifted from a "blue ocean" to a "red ocean," with a significant decline in demand leading to financial losses for major companies like Zhifei Biological and Wantai Biological [1][3][4] Group 1: Market Dynamics - Zhifei Biological reported a 73.06% year-on-year revenue decline to 4.919 billion yuan, with a net loss of 597 million yuan [1] - Wantai Biological, a leader in domestic bivalent vaccines, experienced its first loss since its 2020 IPO, with a revenue drop of 38.25% to 844 million yuan and a net loss of 144 million yuan [1][3] - The market has seen a fundamental reversal in supply and demand, with a saturation of the target population for vaccination [2][4] Group 2: Competitive Landscape - The price of domestic bivalent vaccines has fallen to the range of 200-300 yuan due to increased competition, while imported nine-valent vaccines maintain higher prices but are also offering discounts [2][4] - The sales expense ratio remains high due to fierce competition, further squeezing profit margins [2] Group 3: Growth Challenges - The cumulative vaccination rate for HPV among women aged 9-45 is nearing 20%, indicating that the majority of the target population has already been vaccinated [4] - The imbalance in product structure, with a predominance of bivalent vaccines and a reliance on imported nine-valent vaccines, limits growth potential [4][5] Group 4: Future Opportunities - The male HPV vaccine market is largely untapped, with potential for significant growth as awareness increases [10][12] - Companies are focusing on expanding male indications and international market strategies to overcome current challenges [9][13] - The entry of new competitors and the potential for more HPV vaccines to be approved in the coming years could reshape the market landscape [7][12] Group 5: Strategic Recommendations - There is a need for enhanced public education on the importance of HPV vaccination for both genders to drive demand [11][15] - Companies should focus on high-value vaccine development and optimize supply chain management to avoid inventory issues [15][16]

证券代码：300142 证券简称：沃森生物 公告编号：2025-050 云南沃森生物技术股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 云南沃森生物技术股份有限公司（以下简称"公司"或"沃森生物"）于 2025 年 8 月 25 日召开第五届董事会第三十一次会议和第五届监事会第二十二次 会议，审议通过了《关于转让子公司玉溪沃森生物技术有限公司少数股权暨关联 交易的议案》。现将相关情况公告如下： 一、关联交易概述 1、交易背景 2025 年 5 月 29 日、8 月 4 日和 8 月 12 日，公司先后召开总裁办公会第十四 次、第二十四次和第二十五次会议，最终以上海立信资产评估有限公司出具的评 估报告（信资评报字（2025）第 090076 号）为参考依据，审议通过了《关于签 署<玉溪沃森生物技术有限公司股权转让协议>的议案》，同意公司受让扬州经 开国联硕盈医疗投资合伙企业（有限合伙）（以下简称"国联硕盈基金"）及济 南盈榕创业投资合伙企业（有限合伙）（以下简称"盈榕基金"）分别持有的子 公司玉溪沃森生物技术有限公司（以下简称"玉溪沃森"）的部分少 ...

玉溪沃森生物技术有限公司 审 计 报 告 大信审字[2025]第 5-00075 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 玉溪沃森生物技术有限公司 财务报表附注 2024 年 1 月 1 日—2024 年 12 月 31 日 审 计 报 告 大信审字[2025]第 5-00075 号 玉溪沃森生物技术有限公司： 一、审计意见 我们审计了玉溪沃森生物技术有限公司（以下简称"贵公司"）的财务报表，包括 2024 年 12 月 31 日的资产负债表，2024 年度的利润表、现金流量表、所有者权益变动表，以及财 务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了 贵公司 2024 年 12 月 31 日的财务状况以及 2024 年度的经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对 财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职 业道德守则，我们独立于贵公司，并履行了职业道德方面的其他责任。 ...

人民财讯8月25日电，沃森生物（300142）8月25日晚间披露半年报，公司2025年上半年实现营业收入 11.54亿元，同比下降19.47%；净利润4316.06万元，同比下降74.69%；基本每股收益0.0273元；拟每10 股派发现金红利0.3元(含税)。 ...

格隆汇8月25日丨沃森生物(300142.SZ)公布2025年半年度报告，上半年公司实现营业收入11.54亿元，同 比下降19.47%；归属于上市公司股东的净利润4316.06万元，同比下降74.69%；归属于上市公司股东的 扣除非经常性损益的净利润2844.27万元，同比下降80.52%；基本每股收益0.0273元；拟向全体股东每 10股派发现金红利0.30元(含税)。 ...

云南沃森生物技术股份有限公司 远期外汇交易业务管理制度 云南沃森生物技术股份有限公司 远期外汇交易业务管理制度 （2025年8月修订） 1 目的 2 适用范围 本制度适用于公司及其下属全资子公司、控股子公司（以下简称"子公司"） 开展的远期外汇交易业务。子公司进行远期外汇交易业务视同公司进行远期外汇 交易业务，适用本制度。但未经公司同意，子公司不得操作该业务。 3 术语 3.1 远期外汇交易：特指在银行等金融机构办理的规避和防范汇率风险的远期 外汇交易业务，包括远期结售汇业务、人民币外汇掉期业务等低风险外汇交易。 3.2 远期结售汇业务：是指与银行等金融机构签订远期结售汇合同，约定将来 办理结汇或售汇的外汇币种、金额、汇率和期限，到期再按照该远期结售汇合同 约定的币种、金额、汇率办理结汇或售汇的业务。 为规范云南沃森生物技术股份有限公司（以下简称"公司"）远期外汇交易 业务及相关信息披露工作，加强对远期外汇交易业务的管理，有效防范和控制外 汇风险，保证公司资金安全，根据《中华人民共和国公司法》《中华人民共和国 证券法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业 ...